Trial Profile
A Window Study of Ixazomib in Untreated Indolent B-NHL
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2022
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2020 According to Seattle Cancer Care Alliance (SCCA), media release, data from this study will presented at the 62nd Annual Meeting of the American Society of Hematology, which is being held virtually December 5-8, 2020.